121 related articles for article (PubMed ID: 16518711)
1. Contribution of immunocompetence to the antibacterial activities of ciprofloxacin and moxifloxacin in an in vitro pharmacodynamic model.
Dalhoff A
Infection; 2005 Dec; 33 Suppl 2():44-9. PubMed ID: 16518711
[TBL] [Abstract][Full Text] [Related]
2. Moxifloxacin and ciprofloxacin protect human respiratory epithelial cells against Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, and Haemophilus influenzae in vitro.
Ulrich M; Berger J; Möller JG; Döring G
Infection; 2005 Dec; 33 Suppl 2():50-4. PubMed ID: 16518712
[TBL] [Abstract][Full Text] [Related]
3. Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages.
Vallet CM; Marquez B; Ngabirano E; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
Int J Antimicrob Agents; 2011 Sep; 38(3):249-56. PubMed ID: 21764262
[TBL] [Abstract][Full Text] [Related]
4. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages.
Seral C; Barcia-Macay M; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
J Antimicrob Chemother; 2005 Apr; 55(4):511-7. PubMed ID: 15731197
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
6. Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments.
Nielsen EI; Viberg A; Löwdin E; Cars O; Karlsson MO; Sandström M
Antimicrob Agents Chemother; 2007 Jan; 51(1):128-36. PubMed ID: 17060524
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-pharmacodynamic integration of moxifloxacin in rabbits after intravenous, intramuscular and oral administration.
Fernández-Varón E; Bovaira MJ; Espuny A; Escudero E; Vancraeynest D; Cárceles CM
J Vet Pharmacol Ther; 2005 Aug; 28(4):343-8. PubMed ID: 16050813
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of moxifloxacin and levofloxacin simulating human serum and lung concentrations.
Schubert S; Dalhoff A; Stass H; Ullmann U
Infection; 2005 Dec; 33 Suppl 2():15-21. PubMed ID: 16518707
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic studies of moxifloxacin and erythromycin against intracellular Legionella pneumophila in an in vitro kinetic model.
Tano E; Cars O; Löwdin E
J Antimicrob Chemother; 2005 Jul; 56(1):240-2. PubMed ID: 15919770
[TBL] [Abstract][Full Text] [Related]
10. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
Schafer J; Hovde LB; Simonson D; Rotschafer JC
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
[TBL] [Abstract][Full Text] [Related]
11. Comparison of antibiotic effect and corneal epithelial toxicity of levofloxacin and moxifloxacin in vitro.
Kim SY; Lim JA; Choi JS; Choi EC; Joo CK
Cornea; 2007 Jul; 26(6):720-5. PubMed ID: 17592324
[TBL] [Abstract][Full Text] [Related]
12. Antibacterial activity of ciprofloxacin administered intravenously in a pharmacodynamic in vitro model.
Esposito S; Jansen A
Int J Clin Pharmacol Res; 1991; 11(4):193-9. PubMed ID: 1813438
[TBL] [Abstract][Full Text] [Related]
13. In vitro synergism of beta-lactams with ciprofloxacin and moxifloxacin against genetically distinct multidrug-resistant isolates of Pseudomonas aeruginosa.
Kanellakopoulou K; Sarafis P; Galani I; Giamarellou H; Giamarellos-Bourboulis EJ
Int J Antimicrob Agents; 2008 Jul; 32(1):33-9. PubMed ID: 18538547
[TBL] [Abstract][Full Text] [Related]
14. Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
Huelves L; Sevillano D; Martínez-Marín C; López-Casla MT; Gracia M; Alou L; del Carmen Ponte M; Prieto J; Soriano F;
Int J Antimicrob Agents; 2006 Apr; 27(4):294-9. PubMed ID: 16527462
[TBL] [Abstract][Full Text] [Related]
15. Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model.
Ba BB; Feghali H; Arpin C; Saux MC; Quentin C
Antimicrob Agents Chemother; 2004 Mar; 48(3):946-53. PubMed ID: 14982788
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of antibacterial in vitro activity of moxifloxacin and its effects on pulmonary clearance of Klebsiella pneumoniae in an animal experimental model.
Drago L; De Vecchi E; Nicola L; Gismondo MR
Arzneimittelforschung; 2005; 55(8):473-7. PubMed ID: 16149716
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model.
Singh R; Ledesma KR; Chang KT; Hou JG; Prince RA; Tam VH
J Antimicrob Chemother; 2009 Sep; 64(3):556-62. PubMed ID: 19589810
[TBL] [Abstract][Full Text] [Related]
18. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
Deryke CA; Du X; Nicolau DP
J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
[TBL] [Abstract][Full Text] [Related]
20. The effect of treatment with moxifloxacin or azithromycin on acute bacterial rhinosinusitis in mice.
Luxameechanporn T; Blair C; Kirtsreesakul V; Thompson K; Naclerio RM
Int J Infect Dis; 2006 Sep; 10(5):401-6. PubMed ID: 16564192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]